RENOVIS REPORTS RESULTS FROM NXY-059 TRIAL

Renovis has announced that preliminary results from its Phase IIb cerebral hemorrhagic and NXY-059 treatment (CHANT) safety and tolerability trial with the investigational drug, NXY-059, in acute intracerebral hemorrhage (ICH) showed that the safety and tolerability of NXY-059 was similar to placebo.

NXY-059 and the placebo had comparable mortality rates (20 percent in each group) and no difference was found between the NXY-059 and placebo groups on the secondary endpoint of stroke outcomes after ICH in the study.